Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients

Table 1 Demographics for all subjects and stratified by modulator (lumacaftor/ivacaftor) use

	All subjects (n = 20)	CFTR modulator (n = 9)	No CFTR modulator (n = 11)	P value
Age at MRI (yr)	22.3 (11.3-39.0)	26.4 (16.3-39.0)	21.9 (11.3-36.1)	0.29
Genotype
F508del/F508del	10	9	1	< 0.01
F508del/other	9	0	9	< 0.01
Other/other	1	0	1	< 0.01
Male sex	16 (80%)	7 (78%)	9 (82%)	1.00
BMI percentile	39 (2-96)	51 (3-77)	23 (2-96)	0.21
% predicted FEV1	77 (33-105)	73 (33-89)	77 (48-105)	0.24
CFRD	12 (60%)	7 (78%)	5 (45%)	0.20
Insulin therapy	10 (50%)	6 (67%)	4 (36%)	0.37

Data presented as median (range) or frequency (percent) as appropriate. BMI (percentile): body mass index percentile adjusted for age; FEV1: forced expiratory volume at 1 s; CFRD: cystic fibrosis related diabetes.